399 related articles for article (PubMed ID: 26092578)
1. Infliximab-Related Infusion Reactions: Systematic Review.
Lichtenstein L; Ron Y; Kivity S; Ben-Horin S; Israeli E; Fraser GM; Dotan I; Chowers Y; Confino-Cohen R; Weiss B
J Crohns Colitis; 2015 Sep; 9(9):806-15. PubMed ID: 26092578
[TBL] [Abstract][Full Text] [Related]
2. Rapid infusion of infliximab biosimilars and the incidence and severity of infusion-related reactions in patients with inflammatory bowel disease.
Rusch C; Wood M; Kennedy AG; Tompkins BJ; Frasca JD
J Clin Pharm Ther; 2022 Nov; 47(11):1851-1857. PubMed ID: 36134561
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysis.
Fumery M; Tilmant M; Yzet C; Brazier F; Loreau J; Turpin J; Le Mouel JP; Goeb V; Nguyen-Khac E; Singh S; Dupas JL; Diouf M
Dig Liver Dis; 2019 Apr; 51(4):484-488. PubMed ID: 30686715
[TBL] [Abstract][Full Text] [Related]
5. Transitioning patients with inflammatory bowel disease from hospital-based to rapid home-based infliximab: A stepwise, safety and patient-orientated process towards sustainability.
Bohra A; Rizvi QA; Keung CYY; Vasudevan A; van Langenberg DR
World J Gastroenterol; 2020 Sep; 26(36):5437-5449. PubMed ID: 33024395
[TBL] [Abstract][Full Text] [Related]
6. The incidence and management of infusion reactions to infliximab: a large center experience.
Cheifetz A; Smedley M; Martin S; Reiter M; Leone G; Mayer L; Plevy S
Am J Gastroenterol; 2003 Jun; 98(6):1315-24. PubMed ID: 12818276
[TBL] [Abstract][Full Text] [Related]
7. The Tolerability and Efficacy of Rapid Infliximab Infusions in Patients with Inflammatory Bowel Disease.
Qazi T; Shah B; El-Dib M; Farraye FA
Dig Dis Sci; 2016 Feb; 61(2):589-96. PubMed ID: 26441281
[TBL] [Abstract][Full Text] [Related]
8. Infliximab therapy in children and adolescents with inflammatory bowel disease.
Veres G; Baldassano RN; Mamula P
Drugs; 2007; 67(12):1703-23. PubMed ID: 17683171
[TBL] [Abstract][Full Text] [Related]
9. Incidence and Management of Infusion Reactions to Infliximab in an Alternate Care Setting.
Checkley LA; Kristofek L; Kile S; Bolgar W
Dig Dis Sci; 2019 Mar; 64(3):855-862. PubMed ID: 30311152
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Infliximab Tolerance Induction in Patients with Inflammatory Bowel Diseases who Experienced Acute Infusion Reactions.
Pauchard I; Nancey S; Hacard F; Williet N; Roblin X; Moussata D; Bérard F; Flourié B; Boschetti G
Dig Dis; 2018; 36(6):417-426. PubMed ID: 30130790
[TBL] [Abstract][Full Text] [Related]
11. Infliximab safety profile and long-term applicability in inflammatory bowel disease: 9-year experience in clinical practice.
Zabana Y; Domènech E; Mañosa M; Garcia-Planella E; Bernal I; Cabré E; Gassull MA
Aliment Pharmacol Ther; 2010 Mar; 31(5):553-60. PubMed ID: 20002026
[TBL] [Abstract][Full Text] [Related]
12. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
[TBL] [Abstract][Full Text] [Related]
13. Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis.
O'Meara S; Nanda KS; Moss AC
Inflamm Bowel Dis; 2014 Jan; 20(1):1-6. PubMed ID: 24280879
[TBL] [Abstract][Full Text] [Related]
14. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease.
Clare DF; Alexander FC; Mike S; Dan G; Allan F; Lisa W; Peter HJ
Eur J Gastroenterol Hepatol; 2009 Jan; 21(1):71-5. PubMed ID: 19060632
[TBL] [Abstract][Full Text] [Related]
15. Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies.
Takeuchi T; Nishikawa K; Yamada F; Morita A; Ohtsuki M; Suzuki Y; Watanabe M; Yamanaka H; Hibi T
Drug Saf; 2023 Oct; 46(10):991-1005. PubMed ID: 37700154
[TBL] [Abstract][Full Text] [Related]
16. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis.
Lawson MM; Thomas AG; Akobeng AK
Cochrane Database Syst Rev; 2006 Jul; (3):CD005112. PubMed ID: 16856078
[TBL] [Abstract][Full Text] [Related]
17. Rapid Infliximab Infusion in Children with Inflammatory Bowel Disease: A Multicenter North American Experience.
El-Matary W; Dykes DMH; Bauman L; Elkadri A; Carroll MW; Izaguirre MR; deBruyn J; Samson CM; Crim AM; Ali S; Grossman A
Inflamm Bowel Dis; 2017 Dec; 23(12):2104-2108. PubMed ID: 29140940
[TBL] [Abstract][Full Text] [Related]
18. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
Aardoom MA; Veereman G; de Ridder L
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
[TBL] [Abstract][Full Text] [Related]
19. Infliximab Biosimilars in the Treatment of Inflammatory Bowel Diseases: A Systematic Review.
Radin M; Sciascia S; Roccatello D; Cuadrado MJ
BioDrugs; 2017 Feb; 31(1):37-49. PubMed ID: 28035633
[TBL] [Abstract][Full Text] [Related]
20. Infliximab in inflammatory bowel disease. Is premedication necessary?
Nuñez F P; Quera R; Simian D; Flores L; Figueroa C; Ibañez P; Kronberg U; Lubascher J; Pizarro G
Gastroenterol Hepatol; 2021 May; 44(5):321-329. PubMed ID: 33386199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]